EIP Phar­ma flies in­to a high-risk PhI­Ib Alzheimer’s study fu­eled with $20.5M from bil­lion­aire Len Blavat­nik’s ...

8 years ago
Financing

No­var­tis sac­ri­fices its top at­tor­ney in an at­tempt to quell clam­or over $1.2M in Co­hen pay­ments — while ex-CEO ...

8 years ago
Bioregnum
Opinion

Seat­tle's Nohla clos­es $45M to bring nov­el stem cell treat­ment for leukemia to late-stage tri­als

8 years ago
Financing
Startups

Pfiz­er fi­nal­ly fin­ish­es a 3-year reg­u­la­to­ry odyssey, bag­ging an FDA OK for 1st Epogen knock­off

8 years ago
Pharma

Dai­ichi Sankyo adds $484M pact to its on­go­ing Zymeworks col­lab­o­ra­tion; Sur­face spins out of Im­prim­is with $20M raise

8 years ago
News Briefing

Gilead for­ti­fies its pi­o­neer­ing cell ther­a­py sta­tus, ex­pand­ing in­to three new fa­cil­i­ties and team­ing with NCI

8 years ago
R&D

High pro­file biotech in­vestor Beth Sei­den­berg is ex­it­ing Klein­er Perkins and start­ing her own fund — re­port

8 years ago
People
Financing

Eli Lil­ly touts some mixed PhI­II re­sults for clus­ter headaches as Am­gen, No­var­tis prep a mar­ket-bust­ing move in ...

8 years ago
R&D

Medicxi, RA Cap­i­tal join $30M round for Dutch biotech's late-stage trans­plan­ta­tion med

8 years ago
Financing

Polyphor par­lays a pathogen-spe­cif­ic an­tibi­ot­ic and I/O work in­to a $165M IPO for its PhI­II pro­gram

8 years ago
Financing

Third Rock, GV back Broad spin­out Cel­sius in bid to de­vel­op pre­ci­sion meds for au­toim­mune dis­ease

8 years ago
Financing
Startups

Cam­bridge spin­out Cell­Cen­tric gets $26M for sin­gle-as­set epi­ge­net­ics ap­proach to prostate can­cer

8 years ago
Financing

Wak­sal's gene ther­a­py spin­off MeiraGTx says it’s time to fly with an $86M IPO

8 years ago
Financing

HHS Sec­re­tary Azar pitch­es nam­ing and sham­ing tac­tics on drug price cam­paign, sin­gling out Cel­gene's Revlim­id

8 years ago
Pharma

Tar­get­ing the tricky PI3K path­way in can­cer, MEI gets $75M to push pro­gram through reg­is­tra­tion study

8 years ago
Financing

Chi­na's CStone ramps up yet an­oth­er PD-1 clin­i­cal tri­al for sol­id tu­mors; Take­da faces prof­it de­cline on loss of ...

8 years ago
News Briefing

Trou­bled aTyr ax­es 30% of its staff as it wipes a pre­clin­i­cal slate clean

8 years ago
R&D
Pharma

Eli Lil­ly's on­col­o­gy R&D spree con­tin­ues with $576M deal to buy a start­up and reel back Au­ro­ra A drug

8 years ago
Deals

Blue­bird bio dives deep­er in­to its TCR al­liance with Medi­gene, adding $500M in mile­stones and 2 new tar­gets

8 years ago
R&D
Pharma

CRISPR trail­blaz­ers Zhang, Liu and Joung join forces to launch Beam with $87M and cut­ting-edge gene-edit­ing tech

8 years ago
Financing
Startups

Trump's 'sweep­ing ac­tion' to low­er drug prices mocked by an­a­lysts as re­lieved in­vestors trig­ger ral­ly in Big Phar­ma ...

8 years ago
Pharma

Sen­a­tors Wyden, Mur­ray launch No­var­tis probe: 'What Amer­i­ca has seen here rais­es the specter of cor­rup­tion'

8 years ago
Pharma

Celldex ax­es two more pro­grams to cut costs fol­low­ing glem­bat­u­mum­ab fail­ure; Zio­pharm stock slides on halt­ed brain ...

8 years ago
News Briefing

Jose Car­los 'JC' Gutiér­rez-Ramos hits the ex­it at Syn­log­ic; Rich Hey­man pass­es Oric reins to ex-Igny­ta CFO

8 years ago
Peer Review
First page Previous page 1039104010411042104310441045 Next page Last page
A service from the Financial Times